February 8, 2019 Sequana Medical raises €27.5 million in successful Initial Public Offering Non-regulated
February 7, 2019 Sequana Medical announces the Coverage of the Base Offering of Its Initial Public Offering on Euronext Brussels Non-regulated
January 31, 2019 Sequana Medical Launches Its Initial Public Offering on Euronext Brussels Non-regulated
January 29, 2019 Sequana Medical receives Breakthrough Device designation from the FDA for its alfapump® Non-regulated
November 30, 2018 Sequana Medical Announces Intention to Launch an Initial Public Offering on Euronext Brussels Non-regulated
November 15, 2018 UK NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements Non-regulated
November 8, 2018 Sequana Medical Announces the Appointments of Industry Experts Pierre Chauvineau as Chairman and Wim Ottevaere as Non-Executive Director Non-regulated
November 8, 2018 Sequana Medical Announces Intention to Launch an Initial Public Offering on Euronext Brussels Non-regulated
October 15, 2018 Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders Non-regulated EN
September 17, 2018 Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society Non-regulated EN
